Entheon Issues Incentive Stock Options

Rhea-AI Summary

Entheon Biomedical Corp (OTCQB: ENTBF) has announced the issuance of stock options to company directors. The granted options allow for the purchase of up to 40,000 common shares at an exercise price of $0.145 per share. These options will remain exercisable for a two-year period from the grant date. The options are governed under the company's incentive stock option plan, which was previously approved by shareholders at the annual general meeting on December 16, 2024.

Positive

• Stock options align directors' interests with shareholders

Negative

• Potential shareholder dilution from 40,000 new stock options

News Market Reaction – ENTBF

+3.73%

1 alert

+3.73% News Effect

On the day this news was published, ENTBF gained 3.73%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that the Company has granted options to purchase up to an aggregate 40,000 common shares in the Company (the "Options") to certain directors of the Company. The Options are exercisable at $0.145 per share for a period of two years from the date of grant. The Options have been granted under and are governed by the terms of the Company's incentive stock option plan approved by the Company's shareholders at its annual general meeting held on December 16, 2024.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,
Timothy Ko, CEO, President and Director

For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
timothy@entheonbiomedical.com
https://entheonbiomedical.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246827

FAQ

How many stock options did Entheon Biomedical (ENTBF) grant to directors in March 2025?

Entheon Biomedical granted options to purchase 40,000 common shares to certain directors.

What is the exercise price for Entheon Biomedical's (ENTBF) March 2025 stock options?

The options are exercisable at $0.145 per share.

When do the March 2025 stock options for Entheon Biomedical (ENTBF) expire?

The options expire two years from the date of grant.

When was Entheon Biomedical's (ENTBF) stock option plan approved by shareholders?

The stock option plan was approved at the annual general meeting on December 16, 2024.